A detailed history of Fifth Third Bancorp transactions in Genmab A/S stock. As of the latest transaction made, Fifth Third Bancorp holds 44,576 shares of GMAB stock, worth $917,819. This represents 0.0% of its overall portfolio holdings.

Number of Shares
44,576
Previous 45,256 1.5%
Holding current value
$917,819
Previous $1.14 Million 4.49%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

SELL
$23.84 - $28.48 $16,211 - $19,366
-680 Reduced 1.5%
44,576 $1.09 Million
Q2 2024

Jul 22, 2024

SELL
$25.13 - $30.27 $108,812 - $131,069
-4,330 Reduced 8.73%
45,256 $1.14 Million
Q1 2024

Apr 23, 2024

SELL
$26.43 - $32.77 $9,461 - $11,731
-358 Reduced 0.72%
49,586 $1.48 Million
Q4 2023

Jan 19, 2024

SELL
$27.94 - $35.44 $56,662 - $71,872
-2,028 Reduced 3.9%
49,944 $1.59 Million
Q3 2023

Oct 31, 2023

BUY
$35.27 - $42.24 $1.83 Million - $2.19 Million
51,751 Added 23416.74%
51,972 $1.83 Million
Q1 2023

Apr 24, 2023

BUY
$34.88 - $43.22 $348 - $432
10 Added 4.74%
221 $8,000
Q4 2022

Jan 25, 2023

SELL
$33.8 - $47.06 $1,013 - $1,411
-30 Reduced 12.45%
211 $0
Q3 2022

Oct 25, 2022

SELL
$31.52 - $373.61 $409 - $4,856
-13 Reduced 5.12%
241 $8,000
Q2 2022

Aug 04, 2022

BUY
$26.83 - $38.57 $1,797 - $2,584
67 Added 35.83%
254 $8,000
Q1 2022

Apr 19, 2022

SELL
$30.95 - $39.68 $5,478 - $7,023
-177 Reduced 48.63%
187 $7,000
Q3 2021

Oct 15, 2021

BUY
$41.55 - $48.72 $997 - $1,169
24 Added 7.06%
364 $16,000
Q1 2021

May 07, 2021

SELL
$30.92 - $44.4 $21,272 - $30,547
-688 Reduced 66.93%
340 $11,000
Q4 2020

Feb 16, 2021

BUY
$33.66 - $40.76 $16,156 - $19,564
480 Added 87.59%
1,028 $42,000
Q2 2020

Aug 05, 2020

BUY
$20.05 - $33.89 $3,749 - $6,337
187 Added 51.8%
548 $19,000
Q4 2019

Feb 14, 2020

BUY
$18.88 - $24.14 $6,815 - $8,714
361 New
361 $8,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.6B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Fifth Third Bancorp Portfolio

Follow Fifth Third Bancorp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fifth Third Bancorp, based on Form 13F filings with the SEC.

News

Stay updated on Fifth Third Bancorp with notifications on news.